|
CFCF is pleased to announce that this E-Update is supported by Novartis Pharmaceuticals Corporation |
 Follow us on Twitter!
 Join us on Facebook!
Visit us on Navigating Cancer! |
(submitted 2/22/11)
CFCF is honored to present Survivor Stories. They reflect remarkable courage and determination. Thank you to our Survivors for sharing their courage and words of hope with other patients. Read our newest survivor stories:
|
|
Join Us for a Cure
Make a difference and get involved with CFCF! Unite, meet fellow members of the carcinoid community, and spread awareness at upcoming CFCF events! |
Give hope and a future to neuroendocrine tumor patients: donate to CFCF where 100% of all individual donations go to carcinoid and related neuroendocrine tumor research. CFCF is a 501(c)(3) organization-all contributions are tax-deductible. We want our donors to know that we are allocating their donations responsibly and wisely to achieve a carcinoid cure as quickly as possible.
To learn more, view CFCF's:
Audited Financial Statements
IRS From 990
|
CFCF meets all 20 Wise Giving Alliance standards for charity accountability established by the Better Business Bureau. Click here to check out the CFCF Wise Giving Report. |
|
|
|
|
|
|
Bike to a Cure with Team CFCF!
 Join CFCF in the 2011 Pan Mass Challenge. Team CFCF is a motivated, energetic group that has raised over 1 million dollars for cutting-edge neuroendocrine cancer research. Team CFCF is proud to be sponsored by the Park Plaza Executive Centre.
Riders range from "newbies" to the very experienced. This year CFCF's Chairman Anne Doyle returns as our team captain, riding in her 11th PMC!
You can learn more about Anne (pictured), Craig (pictured), and the rest of Team CFCF here.
For more information or to join Team CFCF for the ride, please click here today! Registration fills up quickly. |
|
Neuroendocrine Tumor Clinical Trials in the News
 Recent clinical trials results have been receiving a lot of attention in the media. Two studies investigating treatments for pancreatic neuroendocrine tumors have been published in a recent issue of the New England Journal of Medicine. The papers cite data from phase 3, placebo-controlled trials of sunitinib malate (Sutent) and everolimus (Afinitor or RAD-001). Both therapies were found to extend progression-free survival for patients with pancreatic neuroendocrine tumors. If you'd like to learn more, please click here.
All patients should discuss any potential treatment or change in care with a physician well-versed in treating patients with neuroendocrine cancer. Please visit CFCF's Doctor Database or call 617.948.2514 for help in finding such a physician.
|
|
Thank You to the Park Plaza Executive Centre
 CFCF is pleased to announce our new partner in the fight against neuroendocrine cancer: The Park Plaza Executive Centre/D.L. Saunders Companies. The Park Plaza Executive Centre will be supporting CFCF's Boston-based athletic events, including the Jimmy Fund Walk and the Pan Mass Challenge. We are grateful for the Park Plaza Executive Centre and D.L. Saunders Companies for their commitment to curing neuroendocrine cancers and look forward to a fruitful partnership. Please note that our telephone number has changed to 617.948.2514. |
|
Share Your Story
In 2005, Nancy Lindholm founded the Caring for Carcinoid Foundation to discover cures for carcinoid, pancreatic neuroendocrine, and related neuroendocrine cancers. CFCF is proud to offer not only Nancy's story, but all patients' stories.
We are grateful to all those who have shared their stories to inspire and unite neuroendocrine cancer patients, families, friends and caregivers.
Click here to read patient stories. Click here to share your story. |
|
CFCF Clinical Trials Neuroendocrine Tumor Patient Education Conference in Los Angeles
 In recent years, clinical trial options for neuroendocrine tumor patients have increased. How can patients evaluate the benefits of one clinical trial vs. another? What do terms like "progression free survival" and "radiographic response" mean?
Join us in Los Angeles on March 19, 2011 for answers to these and other pressing questions regarding current clinical trials for neuroendocrine tumor patients. Click here to view the agenda featuring Dr. Edward Wolin and Dr. Ronald Natale from Cedars-Sinai, Dr. J. Randolph Hecht from UCLA, and Lauren Erb from CFCF.
To ensure that your clinical trials questions are answered, please be sure to submit them to info@caringforcarcinoid.org by March 11, 2011. The conference is part of CFCF's third annual Patient Education Weekend. The weekend will include the Los Angeles 5K Run/Walk (March 19), a Friends of CFCF Luncheon (March 19), and the Los Angeles Marathon (March 20). To learn more about the conference and for details on how to register, please visit CFCF' website or call 617.948.2514. |
|
|
|
|
